{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:19:48Z","timestamp":1792466388913,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgo.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T18:00:32Z","timestamp":1597168832000},"page":"239-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Real-world adverse events associated with CAR T-cell therapy among adults age\u202f\u2265\u202f65\u202fyears"],"prefix":"10.1016","volume":"12","author":[{"given":"Marjorie E.","family":"Zettler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli G.","family":"Phillips Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Klink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet","family":"Gajra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2020.07.006_bb0005","author":"National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program"},{"issue":"1","key":"10.1016\/j.jgo.2020.07.006_bb0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"JULIET investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jgo.2020.07.006_bb0015","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"15(suppl)","key":"10.1016\/j.jgo.2020.07.006_bb0020","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/JCO.2019.37.15_suppl.7555","article-title":"Outcomes of patients (pts) \u2265 65 years of age in ZUMA-1, a pivotal phase 1\/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL)","volume":"37","author":"Neelapu","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.jgo.2020.07.006_bb0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2018-99-120013","article-title":"Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma","volume":"132","author":"Sano","year":"2018","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.jgo.2020.07.006_bb0030","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2019-124750","article-title":"Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jgo.2020.07.006_bb0035","doi-asserted-by":"crossref","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","article-title":"NCCN guidelines insights: B-cell lymphomas, version 3.2019","volume":"17","author":"Zelenetz","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl. 1","key":"10.1016\/j.jgo.2020.07.006_bb0040","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2019-127490","article-title":"Multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas","volume":"134","author":"Riedell","year":"2019","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.jgo.2020.07.006_bb0045","first-page":"793","article-title":"Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics","volume":"134","author":"Kilgore","year":"2019","journal-title":"Healthc Util Cost Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.jgo.2020.07.006_bb0050","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2019-130983","article-title":"Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the center for international blood & marrow transplant research (CIBMTR) cellular therapy (CT) registry","volume":"134","author":"Jaglowski","year":"2019","journal-title":"Blood"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820301454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820301454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:53:53Z","timestamp":1761818033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406820301454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1879406820301454"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2020.07.006","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world adverse events associated with CAR T-cell therapy among adults age\u202f\u2265\u202f65\u202fyears","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}